FrostPharma AB has experienced a strong growth trajectory in recent years, including the strategic acquisition of Abboxia. As part of accelerating the company’s development even further, Magnus Nylén will assume the role of CEO of FrostPharma starting November 3, 2025.
Read the company’s press release here.
For further information, please contact
Karl-Johan Willén
Partner & Investment Manager
Phone: +46 8 459 67 66
Mobile: +46 70 950 88 25
Email: karljohan.willen@priveq.se